Compare AbbVie Inc (ABBV) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck Gold Miners ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while VanEck Gold Miners ETF trades at $73.23. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck Gold Miners ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GDX | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $115.84 |
52-Week Low | $184.85 | $50.79 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
GDX trades at $78.74, up 0.4% with bearish technical signals from moving averages but neutral oscillators. The ETF faces mixed sentiment as gold miners navigate volatile commodity markets, though some analysts highlight attractive valuations and strong fundamentals. Recent additions like Aya Gold & Silver to the ETF portfolio signal ongoing portfolio optimization.
The outlook remains cautious with technical resistance at $80-$83, while fundamental support comes from record free cash flow yields and discounted multiples. Key risks include gold price volatility and energy cost pressures, but central bank demand and portfolio diversification benefits provide long-term tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
